These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 36763238)

  • 1. CAR-T Cell Therapy: the Efficacy and Toxicity Balance.
    Chohan KL; Siegler EL; Kenderian SS
    Curr Hematol Malig Rep; 2023 Apr; 18(2):9-18. PubMed ID: 36763238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies.
    Schorr C; Forindez J; Espinoza-Gutarra M; Mehta R; Grover N; Perna F
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
    Kotch C; Barrett D; Teachey DT
    Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.
    Yamshon S; Gribbin C; Chen Z; Demetres M; Pasciolla M; Alhomoud M; Martin P; Shore T
    Transplant Cell Ther; 2024 Jan; 30(1):73.e1-73.e12. PubMed ID: 37279856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fever Characteristics and Impact on Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy.
    Davis JA; Gaffney KJ; McGann M; Smith D; Edwards K; Baldino E; Bakos K; Butcher C; Greenwell B; Hess BT; Hashmi H
    Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e14-e18. PubMed ID: 36319568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
    Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
    Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
    Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
    Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
    Sterner RC; Sterner RM
    Front Immunol; 2022; 13():879608. PubMed ID: 36081506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
    Brudno JN; Kochenderfer JN
    Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies.
    Kim SJ; Yoon SE; Kim WS
    Ann Lab Med; 2024 May; 44(3):210-221. PubMed ID: 38205527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular therapy: Immune-related complications.
    Oved JH; Barrett DM; Teachey DT
    Immunol Rev; 2019 Jul; 290(1):114-126. PubMed ID: 31355491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of chimeric antigen receptor T-cells in lymphoma.
    Anderson JK; Mehta A
    Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
    [No Abstract]   [Full Text] [Related]  

  • 13. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.
    Schubert ML; Schmitt M; Wang L; Ramos CA; Jordan K; Müller-Tidow C; Dreger P
    Ann Oncol; 2021 Jan; 32(1):34-48. PubMed ID: 33098993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
    Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
    Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome.
    Lakomy T; Akhoundova D; Nilius H; Kronig MN; Novak U; Daskalakis M; Bacher U; Pabst T
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
    Ho M; Zanwar S; Paludo J
    Eur J Haematol; 2024 Feb; 112(2):197-210. PubMed ID: 37545132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
    Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q
    Front Immunol; 2021; 12():720571. PubMed ID: 34421924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma.
    Chen W; Wang Y; Qi K; Shi M; Cao J; Bhansali R; Wang X; Liu Y; Li H; Zhang H; Yan Z; Sang W; Cheng H; Zhu F; Sun H; Li D; Jing G; Zheng J; Li Z; Xu K
    Transplant Cell Ther; 2021 Mar; 27(3):273.e1-273.e5. PubMed ID: 33781540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognizing, defining, and managing CAR-T hematologic toxicities.
    Rejeski K; Subklewe M; Locke FL
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):198-208. PubMed ID: 38066881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
    Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
    Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 27.